Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte announced a positive opinion from the EMA's CHMP for Opzelura cream to treat moderate atopic dermatitis in adults, positioning it as the first steroid-free topical JAK option in the EU for patients who failed standard therapies. The recommendation is supported by Phase 3 TRuE-AD4 data showing 84.3% of patients achieved EASI75 and 70.6% achieved IGA-TS at Week 24, with significant itch relief observed as early as Day 2.
Key figures
- Drug Name
- Opzelura (ruxolitinib) cream
- Phase Of Trial
- Phase 3
- Easi75 week 24
- 84.3%
- Iga ts week 24
- 70.6%
- Patients in study
- 241
- Bsa reduction week 8
- 15.1% to 2.5%
- Global ad prevalence
- 230 million
- Nrs4 response week 8
- 74.3%
- Nrs4 response week 24
- 64.7%
- Adult ad prevalence eu
- 4.4-7.1%
- Adult ad prevalence global
- 4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.